AI English summary of an SEC filing — figures as filed
Agilent Technologies said net revenue for the three months ended January 31, 2025 was $1,681 million, up 1% from the same period last year, and net income was $318 million compared to $348 million in the prior-year period.
Key points
AI summaryAgilent Technologies said net revenue for the three months ended January 31, 2025 was $1,681 million, up 1% from the same period last year, and net income was $318 million compared to $348 million in the prior-year period.
The company said foreign currency movements for the three months had an unfavorable impact of 2 percentage points on revenue growth, with Life Sciences and Diagnostics Markets revenue up 4%, Agilent CrossLab revenue up 1%, and Applied Markets revenue down 4%.
Agilent said cash provided by operating activities for the three months ended January 31, 2025 was $431 million, below $485 million in the same period last year, and cash and cash equivalents as of January 31, 2025 were $1,467 million.
The company said it repurchased and retired 649,857 shares for $90 million under the 2023 repurchase program during the three months, with remaining authorization of approximately $284 million, and paid cash dividends of $0.248 per share, or $71 million in total.
Key figures
Quarter ended January 31, 2025
- Revenue
- $1.7B
- Operating income
- $376M
- Net income
- $318M
- EPS
- $1.11
- Operating cash flow
- $431M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Quarterly Net Revenue $1,681 million, Net Income $318 million
Agilent Technologies said net revenue for the three months ended January 31, 2025 was $1,681 million, up 1% from the same period last year, and net income was $318 million compared to $348 million in the prior-year period.
Source · Based on the MD&A text of the filing
Foreign Currency Impact and Revenue Changes by New Segment
The company said foreign currency movements for the three months had an unfavorable impact of 2 percentage points on revenue growth, with Life Sciences and Diagnostics Markets revenue up 4%, Agilent CrossLab revenue up 1%, and Applied Markets revenue down 4%.
Source · Based on the MD&A text of the filing
Three-Month Operating Cash Flow $431 million
Agilent said cash provided by operating activities for the three months ended January 31, 2025 was $431 million, below $485 million in the same period last year, and cash and cash equivalents as of January 31, 2025 were $1,467 million.
Source · Based on the MD&A text of the filing
2023 Repurchase Program Execution and Dividends
The company said it repurchased and retired 649,857 shares for $90 million under the 2023 repurchase program during the three months, with remaining authorization of approximately $284 million, and paid cash dividends of $0.248 per share, or $71 million in total.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…